Autophagy

KeifeRx Announces the Appointments of Dan Feehan and Alison Finger to Board of Directors

Retrieved on: 
Wednesday, March 27, 2024
Biotechnology, FDA, Health, Other Health, Pharmaceutical, Oncology, Other Science, Mental Health, Research, Hospitals, Genetics, Science, Clinical Trials, Cardiology, Principal, Brain, Policy, White House Fellows, ALS, Auburn House, Business, Lewy body dementias, Foreign Policy, Georgetown University, Harvard Kennedy School, Public policy, Virology, Bristol Myers Squibb, MBBS, Autophagy, House, IND, MBA, Iraq War, St. Lawrence University, B cell, Louisiana House of Representatives, MCAS, Hematology, Mast cell activation syndrome, Representative, Bluebird bio

KeifeRx, an emerging clinical-stage biopharmaceutical company specializing in the discovery and development of new treatment options for neurodegenerative and immune diseases, announces the appointments of Dan Feehan and Alison Finger to its Board of Directors.

Key Points: 
  • KeifeRx, an emerging clinical-stage biopharmaceutical company specializing in the discovery and development of new treatment options for neurodegenerative and immune diseases, announces the appointments of Dan Feehan and Alison Finger to its Board of Directors.
  • KeifeRx is currently conducting optimizing and IND-enabling studies involving four separate formulations – KFRX03, KFRX04, KFRX05, and KFRX06 – with patent life through 2037.
  • Ms. Finger, the Principal at Auburn House Consulting, LLC, serves on the Board of ADMA Biologics, Inc. and is an Advisor at Quantile Health.
  • She previously held Board positions at Decibel Therapeutics, Vascular Biogenics and served as Chief Commercial Officer at Bluebird Bio.

Provectus Biopharmaceuticals Announces Acceptance of Cancer Immunotherapy PV-10 Abstract for HNSCC at AACR 2024 Annual Meeting

Retrieved on: 
Thursday, March 7, 2024
Head, Neck, Chung, Calreticulin, Vaccine, Immunogenic cell death, Endoplasmic reticulum, ICD, HMGB1, Reactive oxygen species, ATP, Poster, Autophagy, Research, Mouse, Abstract

The abstract, which was accepted for a poster presentation, is titled “ PV 10 induces endoplasmic reticulum stress and autophagy, triggering immunogenic cell death and anti-tumor immunity in head and neck squamous cell carcinoma ” (Abstract #6742, Topic Track: Immunology, Session: Vaccines, Antigens, and Antigen Presentation 2).

Key Points: 
  • The abstract, which was accepted for a poster presentation, is titled “ PV 10 induces endoplasmic reticulum stress and autophagy, triggering immunogenic cell death and anti-tumor immunity in head and neck squamous cell carcinoma ” (Abstract #6742, Topic Track: Immunology, Session: Vaccines, Antigens, and Antigen Presentation 2).
  • According to Moffitt’s abstract, “…in vitro findings reveal that PV-10 induces cytotoxicity in both mEER and MTE-RAS cells.
  • Notably, PV-10 promotes a significant increase in [reactive oxygen species], leading to an elevation in late apoptotic cells.
  • At the molecular level, a remarkable activation of endoplasmic reticulum (ER) stress, pro-apoptotic protein, and autophagy markers were observed.

Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies

Retrieved on: 
Wednesday, March 6, 2024
Alzheimer's disease, Research, Neuron, Cognition, Neuroinflammation, SPARC, Conference, Biomarker, Therapy, EEG, Protein, CSF, SHINE, Publication, Autophagy, Pharmaceutical industry

The three posters, which are listed below, summarize proteomic analyses from the completed SEQUEL and SPARC studies, which were conducted in adults with mild-to-moderate Alzheimer’s disease.

Key Points: 
  • The three posters, which are listed below, summarize proteomic analyses from the completed SEQUEL and SPARC studies, which were conducted in adults with mild-to-moderate Alzheimer’s disease.
  • These posters identify candidate protein biomarkers that correlate with improvements observed in SEQUEL participants treated with CT1812, Cognition’s lead candidate.
  • Pathways identified in these proteomic analyses support a role for CT1812 in modulating Aβ biology and neuroinflammation, among other disease-relevant processes.
  • “Analyses of CSF samples from these studies build on our efforts to identify candidate biomarkers of CT1812 treatment effect,” explained Mary Hamby, Ph.D. , VP of research at Cognition Therapeutics.

Coave Therapeutics Receives Grant from the ALS Association to Advance its CTx-TFEB Program as a Potential Treatment for All Forms of ALS

Retrieved on: 
Thursday, February 29, 2024
ALS Association, Senior, ALS, Research, Alzheimer's disease, TFEB, Wang, Neuron, ALP, Hope, Trehalose, Neurodegenerative disease, Protein, Patient, Spinal cord, Gene, Disease, CSO, Diagnosis, Autophagy, AAV, Amyotrophy, Brain

The grant, which will support the development of Coave’s CTx-TFEB program through to preclinical proof-of-concept, has been made through the Association’s Lawrence and Isabel Barnett Drug Development Program .

Key Points: 
  • The grant, which will support the development of Coave’s CTx-TFEB program through to preclinical proof-of-concept, has been made through the Association’s Lawrence and Isabel Barnett Drug Development Program .
  • ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord.
  • Over the course of the disease, people lose the ability to move, to speak, and eventually, to breathe.
  • With this funding and invaluable support from the ALS Association, we are poised to move our CTx-TFEB program forward.

Cepham Introduces Senolytics Inspired by Ayurveda and TCM for Sustainable Aging

Retrieved on: 
Tuesday, February 20, 2024
Ageing, Regeneration, Inflammation, Senolytic, Neuroprotection, Human, Overalls, Traditional Chinese medicine, Cell, Rasayana, Health, Safety, TCM, Notifiable disease, Longevity, Science, Autophagy, Research, DNA, Pharmaceutical industry

SOMERSET, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Cepham , a leader in Ayurvedic nutraceuticals research and sustainable self-care solutions, has announced the expansion of its Sustainable Aging product line to include senolytics, aimed at redefining approaches to healthy aging.

Key Points: 
  • SOMERSET, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Cepham , a leader in Ayurvedic nutraceuticals research and sustainable self-care solutions, has announced the expansion of its Sustainable Aging product line to include senolytics, aimed at redefining approaches to healthy aging.
  • “Cepham’s decision to include senolytics in its Sustainable Aging ingredient offerings reflects our company's commitment to delivering affordable, high-quality, evidence-based, and safe ingredients to customers,” says Christopher Lamb , vice president of commercial strategy at Cepham.
  • The expansion of senolytics in Cepham’s Sustainable Aging product line marks a pivotal moment in the evolution of longevity solutions.
  • For more information about Cepham, Inc. and its Sustainable Aging Product line, please visit https://cepham.com .

Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, February 6, 2024
Biotechnology, Pharmaceutical, Health, Oncology, OS, KIT, European, Investigational New Drug, Trial of the century, DNA, Research, Patient, IND, Autophagy, ASCO, GIST, Public expenditure, FDA, EMA, MAA, Part, Food, Society, TGCT, Gastrointestinal stromal tumor, European Medicines Agency, Sunitinib, Neoplasm, Cancer, INSIGHT, Tenosynovial giant cell tumor, NDA, Nature Medicine, Pharmaceutical industry

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced financial results for the fourth quarter and year ended December 31, 2023 and provided a corporate update.

Key Points: 
  • Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced financial results for the fourth quarter and year ended December 31, 2023 and provided a corporate update.
  • Expects to present updated results from the Phase 1/2 study of vimseltinib in TGCT in the second half of 2024.
  • Expects to initiate a Phase 2 proof-of-concept study of vimseltinib for the treatment of chronic graft versus host disease (cGVHD) in the fourth quarter of 2024.
  • Cost of Sales: Cost of sales were $1.8 million in the fourth quarter of 2023, which includes $0.9 million in cost of product sales, compared to cost of product sales of $0.7 million for the fourth quarter of 2022.

Unveiling the Future of Health: The Peptide Summit 2024

Retrieved on: 
Friday, January 26, 2024
Conditional sentence, Fibromyalgia, Alternative medicine, Specialization, Regenerative medicine, Biology, Trauma, Health, FMP, Summit, Notifiable disease, Autoimmunity, Medicine, Peptide, Heal, Immune system, Autophagy, Toxicity, Inflammation, Ageing, Fine chemical

CARLSBAD, Calif., Jan. 26, 2024 /PRNewswire/ -- DrTalks is proud to announce the upcoming Peptide Summit, a groundbreaking virtual event that will delve into the applications of peptide therapy in anti-aging, health optimization, and chronic disease management. Scheduled for May 20 to 23, 2024, this summit offers free online access to everyone interested in the role of peptides in health and medicine.

Key Points: 
  • The Peptide Summit 2024, hosted by Dr. Jen Pfleghaar, is a premier virtual event focusing on the transformative potential of peptide therapies in health and medicine.
  • Open to everyone, the summit offers practical knowledge in leveraging peptides to regain control over your health.
  • CARLSBAD, Calif., Jan. 26, 2024 /PRNewswire/ -- DrTalks is proud to announce the upcoming Peptide Summit , a groundbreaking virtual event that will delve into the applications of peptide therapy in anti-aging, health optimization, and chronic disease management.
  • Scheduled for May 20 to 23, 2024, this summit offers free online access to everyone interested in the role of peptides in health and medicine.

Combination Therapy and Precision Medicine Spotlighted as the Gold Standard for the Next Generation of Alzheimer's Treatments in the Journal of Prevention of Alzheimer's Disease (JPAD)

Retrieved on: 
Tuesday, January 16, 2024
Fillit, Entrepreneurship, Drug, School, Patient, Biology, Risk, Reno 1868 FC, Science, Research, MD, Oxidative stress, Next Generation, Biomarker, Drug development, Internal medicine, University, Geriatrics, Cancer, Ageing, Neuroprotection, UNLV, Journal, Karolinska Institute, Doctor of Science, Medicine, Autophagy, Therapy, Doctor of Philosophy, Syndrome, IHU, Dementia, Pharmaceutical industry

NEW YORK, Jan. 16, 2024 /PRNewswire/ -- The Journal of Prevention of Alzheimer's Disease (JPAD) with the support of the Alzheimer's Drug Discovery Foundation (ADDF) recently published a comprehensive issue, "The Biology of Aging: Leading The Next Generation of Alzheimer's Drug Development With a Geroscience Focus," which supports the consensus that combination therapy and precision medicine are the future of Alzheimer's treatment. This landmark publication arrives at a critical time in the Alzheimer's research field following significant drug breakthroughs of anti-amyloid therapies and the emergence of the biology of aging as the leading approach for drug development. This issue emphasizes the need to advance new therapies that target the underlying biology of the disease while also offering a roadmap for the next generation of Alzheimer's therapies.

Key Points: 
  • This issue emphasizes the need to advance new therapies that target the underlying biology of the disease while also offering a roadmap for the next generation of Alzheimer's therapies.
  • Each of these novel targets introduces a new and much-needed multi-pronged approach for developing Alzheimer's treatments, which can complement anti-amyloid drugs on the market.
  • The development of future therapies will enhance our growing understanding of the disease and how the various pathways interact to affect the disease state."
  • "This is a noteworthy achievement, as the publication will serve as the first extensive roadmap of non-amyloid pathways with the potential to address the complexity of Alzheimer's disease."

KeifeRx Expands Exclusive Licensing Agreement with Georgetown University to Include Multiple Disease Indications for Portfolio of Novel Tyrosine Kinase Inhibitors

Retrieved on: 
Monday, January 8, 2024
Alzheimer's disease, IND, Georgetown University, Autophagy, B cell, Mast cell activation syndrome, Brain, NCE, TKI, MCAS, MBBS, Growth, ALS

WASHINGTON, Jan. 8, 2024 /PRNewswire/ -- KeifeRx, an emerging clinical-stage biopharmaceutical company specializing in the discovery and development of new treatment options for neurodegenerative and immune diseases, announced today entry into an amended exclusive licensing agreement with Georgetown University to advance the development of novel tyrosine kinase inhibitor (TKI) chemical entities (NCE) for the treatment of multiple disease indications. The amendment provides an extension of the exclusively licensed rights to these four novel chemical entities for the treatment of new disease conditions including inflammatory, mast-cell associated diseases, and oncology, in addition to existing rights in neurodegenerative diseases. KeifeRx is currently conducting optimizing and IND-enabling studies involving four separate formulations of the TKI (renamed KFRX03, KFRX04, KFRX05, and KFRX06) with patent life through 2037.

Key Points: 
  • The amendment provides an extension of the exclusively licensed rights to these four novel chemical entities for the treatment of new disease conditions including inflammatory, mast-cell associated diseases, and oncology, in addition to existing rights in neurodegenerative diseases.
  • KeifeRx is currently conducting optimizing and IND-enabling studies involving four separate formulations of the TKI (renamed KFRX03, KFRX04, KFRX05, and KFRX06) with patent life through 2037.
  • "We look forward to working with the research team at Georgetown University to spearhead the development of KFRX03, KFRX04, KFRX05, and KFRX06 for the treatment of multiple, underserved disease indications.
  • The IP covering these assets extends through 2037, making the portfolio a high-value drug opportunity given its numerous potential disease indications, including Alzheimer's disease, ALS, mast cell activation syndrome (MCAS), and urticaria."

Deciphera Pharmaceuticals Announces Planned 2024 Corporate Milestones Supporting Evolution to a Self-Sustaining, Multi-Product Company

Retrieved on: 
Monday, January 8, 2024
Research, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Gastrointestinal stromal tumor, Food, Neoplasm, IND, INSIGHT, Autophagy, FDA, MAA, Cetuximab, European, Encorafenib, Public expenditure, KIT, NDA, Cancer, European Medicines Agency, Part, TGCT, MEK, Patient, GIST, Pharmaceutical industry

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today highlighted its strategic outlook for 2024 and planned 2024 corporate milestones, and announced preliminary unaudited fourth quarter and full year 2023 revenue.

Key Points: 
  • Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today highlighted its strategic outlook for 2024 and planned 2024 corporate milestones, and announced preliminary unaudited fourth quarter and full year 2023 revenue.
  • Present updated data from the Phase 1/2 study of vimseltinib in TGCT in the second half of 2024.
  • Initiate a Phase 2 proof-of-concept study of vimseltinib for the treatment of cGVHD in the fourth quarter of 2024.
  • Initiate a Phase 1 study for DCC-3084, a potential best-in-class pan-RAF inhibitor, in the first half of 2024.